Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of [18F]EKZ-001 in healthy volunteers

X
Trial Profile

A First-in-Human Study of [18F]EKZ-001 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorine-18 Bavarostat (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis
  • Focus Diagnostic use; First in man; Pharmacokinetics
  • Sponsors Eikonizo Therapeutics
  • Most Recent Events

    • 13 Jul 2020 New trial record
    • 08 Jul 2020 According to an Eikonizo Therapeutics media release, the study was approved by the independent Ethics Committee of the University Hospitals of KU Leuven and was performed in accordance with the World Medical Association Declaration of Helsinki.
    • 08 Jul 2020 According to an Eikonizo Therapeutics media release, the company plans to use [18F]EKZ-001 PET to confirm and quantify brain HDAC6 target engagement by Eikonizo's drug candidates in therapeutic clinical trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top